Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Quality of life results from pembrolizumab vs chemotherapy in gastric or gastroesophageal junction cancer

Share :

ESMO 2019

27 Sep - 1 Oct 2019
Published: 8 Oct 2019
Views: 963
Rating:
Save
Dr Maria Alsina - Vall d'Hebron Instituto de Oncología (VHIO), Barcelona, Spain

Dr Maria Alsina speaks to ecancer at ESMO 2019 in Barcelona about quality of life results from the KEYNOTE-062 study.

The study looked at pembrolizumab with or without chemotherapy vs chemotherapy in patients with advanced gastric or gastroesophageal junction cancer.

Dr Alsina says the study demonstrated that giving the patients pembrolizumab is not inferior to giving them the standard chemotherapy with regards to quality of life. 

 

Related Videos

EAU 2024: Bladder cancer latest
Dr Bernadett Szabados, Dr Félix Guerrero-Ramos, Dr Yohann Loriot, Prof Andrea...
EAU 2024: Bladder cancer latest ( Dr Bernadett Szabados, Dr Félix Guerrero-Ramos, Dr Yohann Loriot, Prof Andrea Necchi and Dr Cosimo De Nunzio )
9 Apr 2024
Nab-paclitaxel as first line treatment of gastrointestinal neuroendocrine...
Dr Lorraine Chantrill - University of Sydney, Sydney, Australia
Nab-paclitaxel as first line treatment of gastrointestinal neuroendocrine carcinomas shows efficacious results ( Dr Lorraine Chantrill - University of Sydney, Sydney, Australia )
9 Feb 2024
Trifluridine/tipiracil and bevacizumab combination gives a prolonged PFS...
Prof Hironaga Satake - Kochi Medical School, Kochi, Japan
Trifluridine/tipiracil and bevacizumab combination gives a prolonged PFS compared to trifluridine/tipiracil monotherapy in mCRC ( Prof Hironaga Satake - Kochi Medical School, Kochi, Japan )
8 Feb 2024
Hodgkin’s and non-Hodgkin’s lymphomas (NHL)
Dr Jose Sandoval Sus - Memorial Healthcare System, Florida, USA
Hodgkin’s and non-Hodgkin’s lymphomas (NHL) ( Dr Jose Sandoval Sus - Memorial Healthcare System, Florida, USA )
8 Jul 2023
Potential benefit to response rates from trastuzumab added to perioperative...
Dr Anna Wagner - The University of Lausanne, Lausanne, Switzerland, Co-chair of...
Potential benefit to response rates from trastuzumab added to perioperative chemotherapy for patients with HER-2+ GC ( Dr Anna Wagner - The University of Lausanne, Lausanne, Switzerland, Co-chair of the EORTC Gastric Cancer Task Force )
6 Jul 2023
The parotid gland; an unusual site of colorectal cancer metastasis
Dr Paula Isabel Franco - St Luke’s Medical Center, Malina, Philippines
The parotid gland; an unusual site of colorectal cancer metastasis ( Dr Paula Isabel Franco - St Luke’s Medical Center, Malina, Philippines )
14 Jun 2023
SOFT study: Clinical relevance of genomic alterations in premenopausal HR+...
Prof Sherene Loi - Peter MacCallum Cancer Centre, Melbourne, Australia
SOFT study: Clinical relevance of genomic alterations in premenopausal HR+, HER2- early breast cancer ( Prof Sherene Loi - Peter MacCallum Cancer Centre, Melbourne, Australia )
28 Mar 2023
The concept of pan-tumour therapeutics
Dr Benedikt Westphalen - Comprehensive Cancer Center München, Munich, Germany
The concept of pan-tumour therapeutics ( Dr Benedikt Westphalen - Comprehensive Cancer Center München, Munich, Germany )
7 Dec 2022
FOLFOXIRI plus panitumumab vs mFOLFOX6/PAN for unresectable RAS and BRAF wild...
Dr Chiara Cremolini - University of Pisa, Pisa, Italy
FOLFOXIRI plus panitumumab vs mFOLFOX6/PAN for unresectable RAS and BRAF wild-type mCC ( Dr Chiara Cremolini - University of Pisa, Pisa, Italy )
6 Jun 2022

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation